Cervical screening co-testing
Cervical screening co-testing has been studied in 1 paper since 2026: none in people yet; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Feb 14, 2026: “Cost-effectiveness of policy options for transformation of cytology-based nationwide cervical cancer screening programme in the Czech Republic: model-based economic evaluation”.
1 paper studies it3 findingsUpdated
See all 1 papers on cervical screening co-testing
- In silico1
What did studies of cervical screening co-testing find?
3Studies of cervical screening co-testing measured 3 outcomes: Incremental cost-effectiveness ratio, cervical cancer mortality and cervical cancer incidence.
Incremental cost-effectiveness ratio
downin silico1
1 study
Incremental cost-effectiveness ratio
downin silico1
Cervical screening co-testing decreases incremental cost-effectiveness ratio in silico (Comparison of cervical screening strategies in the Czech Republic) (Lowest ICER among evaluated strategies).
“The lowest ICER was reported for a strategy combining cytology at two-year intervals and co-testing at four-year intervals from ages 30 to 65.”
In silicoComparison of cervical screening strategies in the Czech RepublicCytology every two years and co-testing every four yearsfemales
medRxivPreprint
Cervical cancer mortality
downin silico1
1 study
Cervical cancer mortality
downin silico1
Cervical screening co-testing decreases cervical cancer mortality in silico.
“only specific co-testing strategies lead to a decrease in incidence and mortality but differ in benefits and economic efficiency.”
In silicoSpecific co-testing strategies compared with annual cytology with co-testing at ages 35, 45, and 55 in the Czech Republicfemales
medRxivPreprint
Cervical cancer incidence
downin silico1
1 study
Cervical cancer incidence
downin silico1
Cervical screening co-testing decreases cervical cancer incidence in silico.
“only specific co-testing strategies lead to a decrease in incidence and mortality but differ in benefits and economic efficiency.”
In silicoSpecific co-testing strategies compared with annual cytology with co-testing at ages 35, 45, and 55 in the Czech Republicfemales
medRxivPreprint